Navigation Links
Anticoagulant does not reduce rate of ischemic events among certain patients undergoing PCI
Date:9/1/2013

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with nonST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013

"Major progress has been made in the management of nonST-segment elevation [a certain pattern on an electrocardiogram] acute coronary syndromes (NSTE-ACS) because of the availability of potent combinations of oral antiplatelet agents, injectable anticoagulants, and increasing use of an invasive strategy. Nevertheless, the risk of adverse outcomes remains substantial, and there is no consensus on a single optimal injectable anticoagulant that can be used across the continuum of care from the emergency setting through revascularization (when applicable)," according to background information in the article. The synthetic intravenous drug otamixaban inhibits thrombin [an enzyme that acts on fibrinogen in blood causing it to clot] generation in a dose-dependent manner. A phase 2 trial showed a reduction in the combined outcome of death or myocardial infarction (heart attack) in patients treated with otamixaban compared with unfractionated heparin (UFH) plus eptifibatide (an antiplatelet drug) and showed similar bleeding rates with otamixaban at midrange doses.

Philippe Gabriel Steg, M.D., of the Universit Paris-Diderot, Sorbonne-Paris Cit, Paris, and investigators with the TAO trial compared the clinical efficacy and safety of otamixaban with that of unfractionated heparin plus eptifibatide in 13,229 patients with NSTE-ACS and a planned early invasive strategy. The trial was conducted at 568 active sites in 55
'/>"/>

Contact: Philippe Gabriel Steg, M.D.
gabriel.steg@bch.aphp.fr
The JAMA Network Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Huntingtons Disease Linked to Reduced Cancer Risk in Study
2. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
3. Decision guide reduced uncertainty over breast cancer prevention, study finds
4. Scoliosis Treatment Might Reduce Need for Surgeries
5. Exercise helps smokers to quit smoking, to remain smoke-free and to reduce the risk of death
6. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
7. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
8. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
9. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
10. Automated breast ultrasound dramatically reduces physician interpretation time
11. Diabetic retinopathy research could reduce screening costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Linda with this important honor,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
(Date:6/1/2015)... Ticket Down announces that the Golden State Warriors ... and now will face the Cleveland Cavaliers in the ... Oracle Arena in Oakland and the Quicken Loans Arena in ... season, the Golden State Warriors were the elite team that ... from their playoff failures from the year and riding the ...
(Date:6/1/2015)... CO (PRWEB) June 01, 2015 Atagi ... they have been named an Ultherapy® Ultra ... Plastic Surgery and Skin Aesthetics is one of only ... as a premier treatment provider. , Atagi Plastic ... in the Denver area has led the practice to ...
(Date:6/1/2015)... 2015 Rio Salado College’s Dental Clinic ... young adults this summer. , The clinics take place Friday, ... 3 p.m. at the Rio Salado Dental Clinic. The clinic ... “A big goal for us is to offer services to ... students,” said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2
... Dental Laser Market, SAN CLEMENTE, Calif., Feb. ... Inc. (Nasdaq: BLTI ) announced the,formation of ... laser,division, Lasers4Dentistry, and a laser therapy division,Technology4Therapy. Jeffrey ... and Keith G. Bateman, Biolase,s former Executive Vice ...
... Va., Feb. 21 Federal Health Information,Technology (IT) spending ... $4.5,billion in 2013 at a compound annual growth rate ... IT market, according to a new report by,INPUT, the ... robust, several things remain in the way of even,more ...
... and Water Reuse are Honored, NEW ... curricular solution for pharmacy education, has been,awarded ... Electronic Publication or,Product from the Professional/Scholarly Publishing ... In addition, the McGraw-Hill,reference, Water Reuse: Issues, ...
... release is available in Spanish . , ... Country, Maria Luisa de Francisco Maiz provided a clinical-forensic evaluation ... that influence the length of legal time periods. , Brain ... only for their high incidence but also because they mainly ...
... There are numerous antidepressant medications currently on ... the debilitating symptoms of depression even with treatment. ... 15th issue of Biological Psychiatry set out to ... serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine ...
... . , Ikerlan-IK4 (CIC microGUNE Microfluidics Unit - ... device that enables the verification of the optimum conditions for ... a microelectrode that measures the impedance and temperature of the ... be monitored from the moment of its extraction, during its ...
Cached Medicine News:Health News:Former Biolase CEO & EVP Launch Technology4Medicine 2Health News:Federal Health IT Market to Reach $4.5 Billion by 2013 2Health News:McGraw-Hill Professional Products Win Awards From Association of American Publishers 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 3Health News:Comparison of venlafaxine and SSRIs in the treatment of depression 2Health News:A device that measures optimum state of an organ prior to transplanting has been patented 2
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... , June 1, 2015 CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... data from a new PET trial showing that the ... in the brain in migraine patients, namely the orbitofrontal ... Tomography (PET) scan, which is an imaging test of the brain, used ...
(Date:6/1/2015)... June 1, 2015  Boston Biomedical, an industry leader ... cancer stem cell (CSC) pathways, will present clinical data ... multiple tumor types at the 2015 American Society of ... . Data presented at ASCO highlight ... that targets STAT3, leading to inhibition of the critical ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... is a latex-free unisex system that ... catheterization designed to reduce the risk ... includes a 100% latex-free Mentor Self-Cath ... tab makes it easy to use, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: